{"id":{"repo_id":"rowan","oai_identifier":"oai:rdw.rowan.edu:etd-4163"},"canonical_url":"https://search.ndltd.org/etd/rowan/oai:rdw.rowan.edu:etd-4163","repository":{"repo_id":"rowan","name":"Rowan University","base_url":"https://rdw.rowan.edu/do/oai/"},"display":{"title":"MECHANISTIC INVESTIGATIONS OF A NOVEL BRAF REGULATORY SWITCH AND BRAFTIDE, AN ALLOSTERIC PEPTIDE INHIBITOR OF BRAF","abstract":"RAF kinases (ARAF/BRAF/CRAF or Raf-1) are serine/threonine kinases in the MAPK (RAS-RAF-MEK-ERK) pathway. The MAPK pathway is crucial in development and normal cell function. These same roles are dysregulated in cancer; BRAF is the most frequently mutated isoform in cancers and in particular, activation loop mutants BRAF V600E/K mutants have the highest mutational incidence. Three FDA approved inhibitors potently inhibit BRAF V600E/K mutants. However, these same inhibitors fail to address the non-V600E/K mutations and result in paradoxical activation of the MAPK pathway. Two strategies were employed to address the limitations of the FDA-approved inhibitors: provide novel regulatory details of RAF kinase and identify the mechanism of action of Braftide, a lead peptide that circumvents paradoxical activation. Both strategies use a chemo-proteomic approach and validation in a physiologically relevant environment with cell-based assays. Using mutational analysis of an identified phosphorylation site of BRAF, we identify a negative regulatory switch of BRAF that decreases downstream MEK phosphorylation by dissociating the known 14-3-3 scaffolding protein interaction and RAF dimerization. Furthermore, crosslinking-mass spectrometry revealed the binding regions of Braftide that disrupt known regulatory mechanisms of BRAF and the CDC37, co-chaperone. Together, these reports resolve foundational mechanisms for next generation inhibitor development for MAPK pathway attenuation","abstract_html":"RAF kinases (ARAF/BRAF/CRAF or Raf-1) are serine/threonine kinases in the MAPK (RAS-RAF-MEK-ERK) pathway. The MAPK pathway is crucial in development and normal cell function. These same roles are dysregulated in cancer; BRAF is the most frequently mutated isoform in cancers and in particular, activation loop mutants BRAF V600E/K mutants have the highest mutational incidence. Three FDA approved inhibitors potently inhibit BRAF V600E/K mutants. However, these same inhibitors fail to address the non-V600E/K mutations and result in paradoxical activation of the MAPK pathway. Two strategies were employed to address the limitations of the FDA-approved inhibitors: provide novel regulatory details of RAF kinase and identify the mechanism of action of Braftide, a lead peptide that circumvents paradoxical activation. Both strategies use a chemo-proteomic approach and validation in a physiologically relevant environment with cell-based assays. Using mutational analysis of an identified phosphorylation site of BRAF, we identify a negative regulatory switch of BRAF that decreases downstream MEK phosphorylation by dissociating the known 14-3-3 scaffolding protein interaction and RAF dimerization. Furthermore, crosslinking-mass spectrometry revealed the binding regions of Braftide that disrupt known regulatory mechanisms of BRAF and the CDC37, co-chaperone. Together, these reports resolve foundational mechanisms for next generation inhibitor development for MAPK pathway attenuation","abstract_has_math":false,"creators":["Yu, Alison"],"institution":null,"degree_name":"Doctor of Philosophy","degree_level":"Dissertation","degree_discipline":"Chemistry and Biochemistry","degree_department":null,"school":null,"contributors":["Zhihong Wang, PhD","Zhiwei Liu, PhD","Hao Zhu, PhD"],"advisors":[],"committee_chairs":[],"committee_members":[],"year":null,"date_issued":"","date_published":null,"updated_at":"2026-11-19T08:59:40Z","subjects":["Allosteric inhibitor","Braftide","CID-BRAF","Phosphorylation","RAF kinase","Biochemistry--Research","Biochemistry, Biophysics, and Structural Biology","Chemistry"],"languages":[],"rights":[],"rights_urls":[],"identifier_entries":[],"person_identifier_entries":[]},"links":{"outbound_url":"https://rdw.rowan.edu/etd/3160","outbound_label":"Repository record","outbound_source":"dc:identifier","record_url":"https://rdw.rowan.edu/etd/3160","record_label":"Repository record","record_kind":"record","record_source":"dc:identifier","download_url":null,"download_label":null,"download_source":null,"access_status":null,"embargo_until":null,"access_note":null},"source_record":{"url":"https://rdw.rowan.edu/do/oai/?verb=GetRecord&metadataPrefix=oai_etdms&identifier=oai%3Ardw.rowan.edu%3Aetd-4163","prefix":"oai_etdms"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:contributor","label":"Contributor","values":["Zhihong Wang, PhD","Zhiwei Liu, PhD","Hao Zhu, PhD"]},{"key":"dc:creator","label":"Author","values":["Yu, Alison"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.available","label":"Dc Date Available","values":["2025-09-26T07:00:00Z"]},{"key":"dc:date.created","label":"Dc Date Created","values":["2023-09-21T07:00:00Z"]},{"key":"thesis:degree_discipline","label":"Discipline","values":["Chemistry and Biochemistry"]},{"key":"thesis:degree_level","label":"Degree Level","values":["Dissertation"]},{"key":"thesis:degree_name","label":"Degree Name","values":["Doctor of Philosophy"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Allosteric inhibitor","Braftide","CID-BRAF","Phosphorylation","RAF kinase","Biochemistry--Research","Biochemistry, Biophysics, and Structural Biology","Chemistry"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier","label":"Identifier","values":["https://rdw.rowan.edu/etd/3160"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["RAF kinases (ARAF/BRAF/CRAF or Raf-1) are serine/threonine kinases in the MAPK (RAS-RAF-MEK-ERK) pathway. The MAPK pathway is crucial in development and normal cell function. These same roles are dysregulated in cancer; BRAF is the most frequently mutated isoform in cancers and in particular, activation loop mutants BRAF V600E/K mutants have the highest mutational incidence. Three FDA approved inhibitors potently inhibit BRAF V600E/K mutants. However, these same inhibitors fail to address the non-V600E/K mutations and result in paradoxical activation of the MAPK pathway. Two strategies were employed to address the limitations of the FDA-approved inhibitors: provide novel regulatory details of RAF kinase and identify the mechanism of action of Braftide, a lead peptide that circumvents paradoxical activation. Both strategies use a chemo-proteomic approach and validation in a physiologically relevant environment with cell-based assays. Using mutational analysis of an identified phosphorylation site of BRAF, we identify a negative regulatory switch of BRAF that decreases downstream MEK phosphorylation by dissociating the known 14-3-3 scaffolding protein interaction and RAF dimerization. Furthermore, crosslinking-mass spectrometry revealed the binding regions of Braftide that disrupt known regulatory mechanisms of BRAF and the CDC37, co-chaperone. Together, these reports resolve foundational mechanisms for next generation inhibitor development for MAPK pathway attenuation"]},{"key":"dc:title","label":"Title","values":["MECHANISTIC INVESTIGATIONS OF A NOVEL BRAF REGULATORY SWITCH AND BRAFTIDE, AN ALLOSTERIC PEPTIDE INHIBITOR OF BRAF"]}]}],"canonical_facts":{"dc:contributor":["Zhihong Wang, PhD","Zhiwei Liu, PhD","Hao Zhu, PhD"],"dc:creator":["Yu, Alison"],"dc:date.available":["2025-09-26T07:00:00Z"],"dc:date.created":["2023-09-21T07:00:00Z"],"dc:description.abstract":["RAF kinases (ARAF/BRAF/CRAF or Raf-1) are serine/threonine kinases in the MAPK (RAS-RAF-MEK-ERK) pathway. The MAPK pathway is crucial in development and normal cell function. These same roles are dysregulated in cancer; BRAF is the most frequently mutated isoform in cancers and in particular, activation loop mutants BRAF V600E/K mutants have the highest mutational incidence. Three FDA approved inhibitors potently inhibit BRAF V600E/K mutants. However, these same inhibitors fail to address the non-V600E/K mutations and result in paradoxical activation of the MAPK pathway. Two strategies were employed to address the limitations of the FDA-approved inhibitors: provide novel regulatory details of RAF kinase and identify the mechanism of action of Braftide, a lead peptide that circumvents paradoxical activation. Both strategies use a chemo-proteomic approach and validation in a physiologically relevant environment with cell-based assays. Using mutational analysis of an identified phosphorylation site of BRAF, we identify a negative regulatory switch of BRAF that decreases downstream MEK phosphorylation by dissociating the known 14-3-3 scaffolding protein interaction and RAF dimerization. Furthermore, crosslinking-mass spectrometry revealed the binding regions of Braftide that disrupt known regulatory mechanisms of BRAF and the CDC37, co-chaperone. Together, these reports resolve foundational mechanisms for next generation inhibitor development for MAPK pathway attenuation"],"dc:identifier":["https://rdw.rowan.edu/etd/3160"],"dc:subject":["Allosteric inhibitor","Braftide","CID-BRAF","Phosphorylation","RAF kinase","Biochemistry--Research","Biochemistry, Biophysics, and Structural Biology","Chemistry"],"dc:title":["MECHANISTIC INVESTIGATIONS OF A NOVEL BRAF REGULATORY SWITCH AND BRAFTIDE, AN ALLOSTERIC PEPTIDE INHIBITOR OF BRAF"],"thesis:degree_discipline":["Chemistry and Biochemistry"],"thesis:degree_level":["Dissertation"],"thesis:degree_name":["Doctor of Philosophy"]},"updated_at":"2026-11-19T08:59:40Z"}